Glofitamab,Obinutuzumab,Tocilizumab
roche
['glofitamab']
durable responses with fixed duration glofitamab. 24m docr 79%. curative potential of this strategy. retreatment of relapsing patients after achieving cr can induce a new cr. can we switch from continuous treatment to fix duration with bispecific antibodies? #ash22 
hematologa en Fleming, lymphoma fan, mama de Luchi, un poco yogi y mucha acuarela!